Annexin presents at Redeye’s Fight Cancer event on January 24
Kurs
-3,96%
Likviditet
0,07 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2026-02-05 | 08:30 | Bokslutskommuniké 2025 |
| 2025-10-23 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-07-17 | 08:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-15 | - | Årsstämma |
| 2025-04-16 | 08:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-06 | 08:30 | Bokslutskommuniké 2024 |
| 2024-10-17 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-09 | - | Extra Bolagsstämma 2024 |
| 2024-07-18 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-23 | - | X-dag ordinarie utdelning ANNX 0.00 SEK |
| 2024-05-02 | - | Årsstämma |
| 2024-04-12 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-09 | - | Bokslutskommuniké 2023 |
| 2023-11-24 | - | Extra Bolagsstämma 2023 |
| 2023-10-18 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-03 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | Årsstämma |
| 2023-05-24 | - | X-dag ordinarie utdelning ANNX 0.00 SEK |
| 2023-05-17 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-07 | - | Bokslutskommuniké 2022 |
| 2022-11-03 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-30 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-25 | - | X-dag ordinarie utdelning ANNX 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-02-03 | - | Bokslutskommuniké 2021 |
| 2021-11-24 | - | Kvartalsrapport 2021-Q3 |
| 2021-10-08 | - | Extra Bolagsstämma 2021 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | X-dag ordinarie utdelning ANNX 0.00 SEK |
| 2021-05-26 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-04 | - | Bokslutskommuniké 2020 |
| 2020-10-29 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-27 | - | X-dag ordinarie utdelning ANNX 0.00 SEK |
| 2020-05-26 | - | Årsstämma |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-01-28 | - | Extra Bolagsstämma 2019 |
| 2020-01-28 | - | Bokslutskommuniké 2019 |
| 2019-10-31 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | X-dag ordinarie utdelning ANNX 0.00 SEK |
| 2019-05-22 | - | Årsstämma |
| 2019-05-02 | - | Kvartalsrapport 2019-Q1 |
| 2019-01-31 | - | Bokslutskommuniké 2018 |
| 2018-08-20 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | X-dag ordinarie utdelning ANNX 0.00 SEK |
| 2018-05-16 | - | Årsstämma |
| 2018-05-02 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-19 | - | Extra Bolagsstämma 2018 |
| 2018-01-31 | - | Bokslutskommuniké 2017 |
| 2017-10-31 | - | Kvartalsrapport 2017-Q3 |
| 2017-10-02 | - | Extra Bolagsstämma 2017 |
| 2017-08-16 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-15 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-17 | - | Årsstämma |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Annexin Pharmaceuticals today announces that the company is participating at Redeye’s theme event Fight Cancer on January 24, 2024. CEO Anders Haegerstrand will present the latest development in the company’s cancer initiative with the drug candidate ANXV.
The presentation and moderated Q&A session will be held in English and is broadcasted live via Redeye’s website https://www.redeye.se/events/966280/redeye-theme-fight-cancer-2?tab=schedule
The presentation will also be available at Annexin’s website afterwards at https://annexinpharma.se/investerare/presentationer/
Time: January 2024 at 15:56 CET
Place: Redeye, Mäster Samuelsgatan 42, Stockholm
For further information, please contact:
Anders Haegerstrand, CEO
Phone: +46 (0)70 575 50 37
Mail: anders.haegerstrand@annexinpharma.com
About Annexin Pharmaceuticals AB
Annexin Pharmaceuticals AB is a leading biotechnology company in the Annexin A5 field for the treatment of various diseases. The company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for treatment of patients with injuries and inflammation of the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment of diseases with Annexin A5 and for production of Annexin A5.
The Company is based in Stockholm, Sweden and listed on Nasdaq First North Growth Market, under the ticker ANNX. Redeye is the company´s Certified Adviser.